Clinical trial
Erlotinib Before and After Surgery in Treating Patients With Muscle-Invasive…
NCT00380029 · UNC Lineberger Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00380029 |
|---|---|
| Title | Erlotinib Before and After Surgery in Treating Patients With Muscle-Invasive Bladder Cancer |
| Official title | A Phase II Study of Erlotinib (Tarceva®) in Patients With Muscle-Invasive Bladder Cancer Undergoing Radical Cystectomy |
| Lead sponsor | UNC Lineberger Comprehensive Cancer Center, Other |
| Collaborators | OSI Pharmaceuticals Industry National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Bladder Cancer |
| Intervention type | Drug, Procedure |
| Interventions | Erlotinib, Radical Cystectomy |
| Enrollment | 27 |
| Start date | May 1, 2006 |
| Primary completion | Aug 1, 2010 |
| Completion | Jun 1, 2014 |
| First posted | Sep 25, 2006 |
| Last update posted | Jul 19, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: